undamentalytics Newsletter
Sign in

Impact Biomedical Inc. (IBO) stock

Add to watchlist

Add holding +

NYSE: IBO NYSE Biotechnology

Impact Biomedical Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for Impact Biomedical Inc. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: data-quality checks not passed. We'll show the comparison once resolved.

Impact Biomedical Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 3 selling0 purchases and 6 sales by directors and officers, last 12 monthsInsider trades
  • Funds6 adding, 5 cuttingOf 3 active managers that changed their stake, 2 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Loss-making. Operating margin is -14597.1%: costs exceed revenue.
  • Burning cash. Free cash flow was -4717.1% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 4140.0% of revenue: a real cost that cash-flow figures leave out.
  • Volatile shares. Over the past year the shares showed annualised volatility of 129% and a beta of -0.3 against the S&P 500.
  • Weak cash conversion. Free cash flow was -209% of net income over the last 12 months.

Latest results: FY2026 Q2

Filed August 7, 2026
Revenue
$0m, down 57.1% on a year earlier

Impact Biomedical's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+5.5%
  • 1 week+7.5%
  • 1 month-24.6%
  • This year-37.3%
  • 1 year-40.8%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$35,000
Operating margin
-14597.1%
Net margin
2254.3%
EPS (TTM, diluted)
$0.07

Cash

Free cash flow (TTM)
-$1.7M
FCF margin
-4717.1%
Stock pay % of revenue
4140.0%

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Governance
  2. Announcement
  3. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Impact Biomedical Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: data-quality checks not passed.

Valuation multiples over time Market data may be delayed

At fiscal year end 2025
Share price$6.39
Market value$202m
+ Net debt (− = net cash)−$3000
Enterprise value$202m
Multiples
Price / sales n/m
Price / earnings —
Price / free cash flow —
EV / EBITDA —

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

No analyst estimates are published for Impact Biomedical Inc.: too few analysts cover it.

Positioning

Short interest
2.8%
of tradable shares
Days to cover
1.9
at average volume
Short interest, 1 month
−37%
to October 15, 2026
Held by institutions
4%
of shares
Held by insiders
89.0%
of shares
Employees
2
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 20252026 to date
Return
IBO−65%−37%
Industry peers (median)−5%−26%
S&P 500+18%+11%
Months that ended higher
IBO42%36%
S&P 50075%46%
Largest fall from a high during the year
IBO−93%−73%
S&P 500−19%−9%

Worst fall since September 16, 2024: 96% from March 21, 2025 to October 16, 2026. Getting back needed a 2243% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$2.68 – $9.87
From 52-week high
−59.4%
vs 50-day average
−21.8%
vs 200-day average
−36.0%
Volatility (1 year)
129%
Beta vs S&P 500
-0.33

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2022 Dec 2022 2025 Dec 2025 LTM Jun 2026
Income
Revenue 0 0 0
Gross profit — −0 —
EBITDA −2 −3 −4
Operating income −3 −4 −5
Net income −7 −12 1
Diluted EPS −$0.10 −$0.38 —
Growth (year on year)
Revenue — −36.0% —
Margins
Gross margin — <−999% —
EBITDA margin <−999% <−999% <−999%
Operating margin <−999% <−999% <−999%
Net margin <−999% <−999% >999%
Cash flow
Cash from operations −2 −2 −1
Stock-based pay — 0 1
Balance sheet
Cash 0 0 —
Total debt 10 0 0
Net debt (negative = net cash) 10 −0 —
Diluted shares 70m 32m —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

0 of 3 checks passed · June 30, 2026
What it owns · $17m
Short-term assets $0mLonger-term assets $16m
What it owes, and who funded it · $13m
Short-term liabilities $2mLonger-term liabilities $1mShareholders' equity $11m
  • Short-term assets cover short-term liabilities $320,000 of assets due within a year against $2m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $320,000 short-term assets against $688,000 of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of −$5m against $793,000 of interest.

From Impact Biomedical Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

R&D spending
811.4%
of revenue
Sales & admin spending
6188.6%
of revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated IBO LYEL AIM IBIO LSTA CLDX Median
Revenue, last 12 months $35000 $27000 $95000 $100000 $100000 $158000 $55m
Revenue growth, last 12 months — −55.0% −21.5% −75.0% −90.7% −97.3% 12.6%
Revenue growth, 3-year average — −91.8% −17.3% −62.4% — −63.5% 13.7%
Revenue growth, latest quarter −57.1% −50.0% 4.0% −100.0% −100.0% −97.0% 10.2%
Gross margin — — −968.5% 59.9% 7.7% — 82.9%
Operating margin <−999% <−999% <−999% <−999% <−999% <−999% −191.1%
Operating margin, 3-year average — <−999% <−999% <−999% <−999% <−999% −363.5%
Net margin >999% <−999% <−999% <−999% <−999% <−999% −163.5%
Cash from operations / revenue <−999% <−999% <−999% <−999% <−999% <−999% −168.8%
Free-cash-flow margin <−999% <−999% <−999% <−999% <−999% <−999% −168.1%
Free-cash-flow margin, 3-year average — <−999% <−999% <−999% <−999% <−999% −310.0%
Stock pay / revenue >999% >999% 0.0% >999% >999% >999% 20.7%
Change in share count — — 49.8% 13.9% 5.1% 4.7% 8.2%

Median of all 185 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Who owns it

Funds buying and selling
Reported value
$1.8M
Institutions reporting
19
Shares held vs prior quarter
▲ 3.0%
Positions opened / closed
2 / 1

Top buyers and sellers, Q2 2026: 6 institutions bought and 5 sold ; the biggest buyer was Vanguard Capital Management LLC (+101K shares) and the biggest seller UBS Group AG (−30K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Geode Capital Management, LLC $545,578 1.2M 30.9% ▼ 0.7%
Vanguard Capital Management LLC $371,997 809K 21.1% ▲ 14.2%
State Street Corp $279,633 608K 15.9% 0.0%
Vanguard Fiduciary Trust Co $271,137 589K 15.4% ▲ 0.7%
Blackrock, Inc. $119,575 260K 6.8% 0.0%
Northern Trust Corp $108,319 235K 6.1% ▼ 3.5%
Citadel Advisors LLC $22,801 50K 1.3% New
Vanguard Global Advisers, LLC $14,812 32K 0.8% 0.0%
Jane Street Group, LLC $11,282 25K 0.6% New
Two Sigma Investments, LP $7,908 17K 0.4% ▼ 54.1%
Mason & Associates Inc $4,600 10K 0.3% 0.0%
Morgan Stanley $4,272 9K 0.2% ▲ 0.1%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Impact Biomedical Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $59,451 6 trades by 3 insiders · 0% under pre-set plans
Net ▼ $59,451 net selling
Insider Date Trade Shares Price Value
Dss, Inc. 10% owner September 24, 2026 Sell 156 $7.06 $1,101
Dss, Inc. 10% owner September 23, 2026 Sell 27 $6.95 $188
Dss, Inc. 10% owner September 22, 2026 Sell 723 $0.55 $398
Macko Todd D Chief Financial Officer March 27, 2026 Sell 43,400 $0.56 $24,304
Macko Todd D Chief Financial Officer March 25, 2026 Sell 1,600 $0.60 $960
Grady Jason Director March 23, 2026 Sell 50,000 $0.65 $32,500

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Recent SEC filings

Data status

When each part of this page on Impact Biomedical Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Impact Biomedical Inc. in brief

What does Impact Biomedical Inc. do?
Impact Biomedical Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Impact Biomedical Inc.'s stock ticker?
Impact Biomedical Inc. trades under the ticker IBO on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Impact Biomedical Inc.'s free cash flow?
Impact Biomedical Inc.'s free-cash-flow margin is -4717.1% of revenue over the trailing twelve months.
Who are Impact Biomedical Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Geode Capital Management, LLC, Vanguard Capital Management LLC and State Street Corp. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Impact Biomedical Inc.'s market cap?
On December 31, 2025, Impact Biomedical Inc.'s market capitalisation was about $202M and net debt of -$3,000. Market figures come from third-party market data and may be delayed.
Who are Impact Biomedical Inc.'s competitors?
In our Biotechnology peer group, the companies closest to Impact Biomedical Inc. are Lyell Immunopharma, Inc., AIM Immunotech Inc., Ibio, Inc., Lisata Therapeutics, Inc. and Celldex Therapeutics, Inc. The side-by-side comparison below sets their revenue, margins and growth against Impact Biomedical Inc.'s.
Are insiders buying or selling Impact Biomedical Inc. stock?
Over the last 12 months, Impact Biomedical Inc.'s directors and officers reported 0 open-market purchases and 6 sales on Form 4. The insider trading page charts every trade.